Ann Neurol. 1992 Jul;32(1):94-7. doi: 10.1002/ana.410320115.
We report the one-year assessment of plasma exchange (PE) versus control in Guillain-Barré syndrome (GBS), based on a randomized multicenter clinical trial of 220 patients with GBS. Treated patients received four PEs, with either albumin or fresh frozen plasma (FFP) as replacement fluid. This study completes the short-term analysis previously published (Ann Neurol 1987;22: 753-761). Long-term benefit from PE was observed, as demonstrated by full muscular strength recovery at one year: 71% in the PE group versus 52% in the control group (p = 0.007), confirmed after adjustment for four prognostic factors. FFP showed no additional benefit compared with albumin (77% full recovery in the FFP group versus 65% in the albumin group; p = 0.22). PE did not affect the incidence of severe motor disability (11% in both groups).
我们基于一项针对220例吉兰-巴雷综合征（GBS）患者的随机多中心临床试验，报告了血浆置换（PE）与对照治疗GBS的一年期评估结果。接受治疗的患者接受了4次PE治疗，置换液为白蛋白或新鲜冰冻血浆（FFP）。本研究完成了先前发表的短期分析（《神经病学纪事》1987年；22: 753 - 761）。观察到PE具有长期益处，表现为一年时肌肉力量完全恢复：PE组为71%，而对照组为52%（p = 0.007），在对四个预后因素进行调整后得到证实。与白蛋白相比，FFP未显示出额外益处（FFP组完全恢复率为77%，白蛋白组为65%；p = 0.22）。PE不影响严重运动功能障碍的发生率（两组均为11%）。
